Program By Day

7:00 AM-7:55 AM

Rapid-Fire Abstract Session: Cancers of the Colon, Rectum, and Anus

Michael J. Hall, MD, MS - Chair
Fox Chase Cancer Center 

 

Abstract 557: Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

First author: Kohei Shitara, MD

 

Question and Answer

 

Abstract 558: SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.

First author: Mark Saunders, MD, PhD

 

Question and Answer

 

Abstract 559: Effect of physical activity trackers and daily text messages on quality-of-life in colorectal survivors (Smart Pace): A pilot randomized controlled trial.

First author: Hilary Chan, BA

 

Question and Answer

 

Abstract 560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

First author: Johanna Bendell, MD

 

Question and Answer

7:00 AM-7:55 AM Poster Session C: Cancers of the Colon, Rectum, and Anus
7:00 AM-7:55 AM Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
7:00 AM-7:55 AM Breakout Session: Intraperitoneal Chemotherapy for Intra-abdominal Malignancies

Daniel Tandel Chang, MD - Chair
Stanford University School of Medicine

Debate: Colorectal Cancer With Peritoneal Metastasis—A Regional Disease Requiring Regional Therapy

Edward Allen Levine, MD
Wake Forest University
Pro

Garrett Michael Nash, MD, MPH
Memorial Sloan Kettering Cancer Center
Con

Steven Arthur Ahrendt, MD
University of Colorado School of Medicine
Appendiceal Tumors and Peritoneal Mesotheliomas

Panel Question and Answer
7:00 AM-7:55 AM Breakout Session: Liquid Biopsies—Role in Management of Gastrointestinal Cancers

Ash A. Alizadeh, MD, PhD
Stanford Cancer Institute
Overview of Technology: Circulating Tumor Cells and DNA

Ryan Bruce Corcoran, MD, PhD
Massachusetts General Hospital
Clinical Implications of Liquid Biopsies

Panel Question and Answer
7:00 AM-7:55 AM Complimentary Continental Breakfast
7:55 AM-9:30 AM

Welcome and General Session 7: Early-Onset Colorectal Cancer

Rodrigo Jover, MD, PhD - Chair
Alicante University General Hospital

Andrew T. Chan, MD, MPH - Chair
Massachusetts General Hospital/ Harvard Medical School

Karyn A. Goodman, MD, MS
University of Colorado Cancer Center
Welcome of the Day

Joseph J.Y. Sung, MD, PhD, MBBS
The Chinese University of Hong Kong
Epidemiology of Early-Onset Colon Cancer

Fay Kastrinos, MD, MPH
Columbia University Medical Center
Health Disparities, Screening, and Prevention

Irit Ben-Aharon, MD, PhD
Davidoff Cancer Center
Clinical Management and Survivorship Issues

 

 

Abstract 552: Age distribution of tumor gene expression in patients with stage II/III colon cancer.

First author: Howard Hochster, MD



Panel Question and Answer

9:30 AM-10:00 AM Break
10:00 AM-11:00 AM Keynote Lecture: Mapping the Immune Landscape in Pancreatic Cancer

Steven D. Leach, MD
Dartmouth Norris Cotton Cancer Center
11:00 AM-12:30 PM

Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

S. Gail Eckhardt, MD, FASCO - Chair
The University of Texas at Austin Dell Medical School

Mary Uan-Sian Feng, MD  - Chair
University of California, San Francisco

 

Abstract 553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

First author: Thierry Andre, MD

 

Abstract 554: Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

First author: Michael Overman, MD

 

Zsofia Kinga Stadler, MD
Memorial Sloan Kettering Cancer Center

Discussion 

 

Abstract 555: Genetic profile of polyps and risk of advanced metachronous lesions.

First author: Oscar Murcia Sr., MD

 

Abstract 556: Prospective clinical study of circulating tumor cells for colorectal cancer screening.

First author: Wen-Sy Tsai, MD, PhD

 

Douglas Corley, MD, PhD, MPH
Kaiser Permanente

Discussion

 

Panel Question and Answer

12:30 PM-2:00 PM Poster Session C: Cancers of the Colon, Rectum, and Anus
With Complimentary Boxed Lunch
12:30 PM-2:00 PM Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
1:00 PM-1:45 PM

Poster Walks

Open to all attendees. Meet at the Poster Assistance Desk. 

 

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center

 

George Fisher, MD
Stanford University School of Medicine

2:00 PM-3:00 PM General Session 8: Controversies in Adjuvant Therapy for Colorectal Cancer (ARS)

Frank A. Sinicrope, MD - Chair
Mayo Clinic

Karyn A. Goodman, MD, MS - Chair
University of Colorado Cancer Center

Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough?

Jeffrey A. Meyerhardt, MD, MPH, FASCO
Dana-Farber Cancer Institute/ Partners Cancer Care
U.S. Perspective

Timothy Iveson, MD, FRCP
University Hospital Southampton NHS Foundation Trust
European Perspective

Role of (Neo)Adjuvant Chemotherapy for Rectal Cancer: U.S. Versus European Approach

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center
U.S. Perspective

Cornelis J. H. Van De Velde, MD, PhD
Leiden University Medical Center
European Perspective

Panel Question and Answer
3:00 PM-3:15 PM Break
3:15 PM-4:30 PM General Session 9: Contemporary Management of Colorectal Cancer Liver Metastases (ARS)

Flavio G. Rocha, MD - Chair
Virginia Mason Hospital and Medical Center

Michael J. Hall, MD, MS - Chair
Fox Chase Cancer Center

Case Presentation and Discussion

Guy A. Van Hazel, FRACP, FRCP, MBBS
Sir Charles Gairdner Hospital
Medical Oncologist Perspective

Alejandra Méndez Romero, MD, PhD
Erasmus Medical Center
Radiation Oncologist Perspective

Mark Hull, MD, PhD
University of Leeds
Clinician Scientist Perspective

Rene Adam, MD, PhD
Paul Brousse Hospital, France
Surgeon Perspective